Autolus Therapeutics plc
AUTL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $10,120 | $1,698 | $6,194 | $1,507 |
| % Growth | 496% | -72.6% | 311% | – |
| Cost of Goods Sold | $141,020 | $0 | $0 | $0 |
| Gross Profit | -$130,900 | $1,698 | $6,194 | $1,507 |
| % Margin | -1,293.5% | 100% | 100% | 100% |
| R&D Expenses | $158,136 | $130,481 | $117,354 | $110,839 |
| G&A Expenses | $0 | $46,745 | $31,899 | $31,865 |
| SG&A Expenses | $0 | $46,745 | $31,899 | $31,865 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$47,610 | $4,173 | -$166 | -$823 |
| Operating Expenses | $110,526 | $181,399 | $149,087 | $141,881 |
| Operating Income | -$241,426 | -$179,701 | -$142,893 | -$140,374 |
| % Margin | -2,385.6% | -10,583.1% | -2,307% | -9,314.8% |
| Other Income/Exp. Net | $22,292 | -$28,701 | -$5,674 | -$1,664 |
| Pre-Tax Income | -$219,134 | -$208,402 | -$148,567 | -$142,038 |
| Tax Expense | $1,528 | -$19 | $272 | $58 |
| Net Income | -$220,662 | -$208,383 | -$148,839 | -$142,096 |
| % Margin | -2,180.5% | -12,272.3% | -2,403% | -9,429.1% |
| EPS | -0.87 | -1.2 | -1.57 | -1.97 |
| % Growth | 27.5% | 23.6% | 20.3% | – |
| EPS Diluted | -0.87 | -1.2 | -1.57 | -1.97 |
| Weighted Avg Shares Out | 255,161 | 173,942 | 94,993 | 72,084 |
| Weighted Avg Shares Out Dil | 255,161 | 173,942 | 94,993 | 72,084 |
| Supplemental Information | – | – | – | – |
| Interest Income | $32,355 | $13,505 | $1,708 | $262 |
| Interest Expense | $9,294 | $45,067 | $8,905 | $1,105 |
| Depreciation & Amortization | $7,716 | $6,565 | $7,422 | $8,458 |
| EBITDA | -$233,073 | -$156,770 | -$132,240 | -$132,475 |
| % Margin | -2,303.1% | -9,232.6% | -2,135% | -8,790.6% |